Recent progress in TGF-β inhibitors for cancer therapy

Cheng Yi Huang, Chih Ling Chung, Tsung Hui Hu, Jih Jung Chen, Pei Feng Liu, Chun Lin Chen*

*此作品的通信作者

研究成果: Review article同行評審

86 引文 斯高帕斯(Scopus)

摘要

Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now. Unfortunately, several of these programs have recently been relinquished, and most companies that remain in the contest are progressing slowly and cautiously. This review summarizes the TGF-β signal transduction pathway, its roles in oncogenesis and fibrotic diseases, and advancements in antibodies and small-molecule inhibitors of TGF-β.

原文English
文章編號111046
期刊Biomedicine and Pharmacotherapy
134
DOIs
出版狀態Published - 2月 2021

指紋

深入研究「Recent progress in TGF-β inhibitors for cancer therapy」主題。共同形成了獨特的指紋。

引用此